@article{KronerWeiglChuRudertetal.2023,
  author    = {Kroner-Weigl, Niklas and Chu, Jin and Rudert, Maximilian and Alt, Volker and Shukunami, Chisa and Docheva, Denitsa},
  title     = {Dexamethasone is not sufficient to facilitate tenogenic differentiation of dermal fibroblasts in a 3D organoid model},
  series = {Biomedicines},
  volume    = {11},
  journal   = {Biomedicines},
  number    = {3},
  issn      = {2227-9059},
  doi       = {10.3390/biomedicines11030772},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-311234},
  year      = {2023},
  abstract  = {Self-assembling three-dimensional organoids that do not rely on an exogenous scaffold but maintain their native cell-to-cell and cell-to-matrix interactions represent a promising model in the field of tendon tissue engineering. We have identified dermal fibroblasts (DFs) as a potential cell type for generating functional tendon-like tissue. The glucocorticoid dexamethasone (DEX) has been shown to regulate cell proliferation and facilitate differentiation towards other mesenchymal lineages. Therefore, we hypothesized that the administration of DEX could reduce excessive DF proliferation and thus, facilitate the tenogenic differentiation of DFs using a previously established 3D organoid model combined with dose-dependent application of DEX. Interestingly, the results demonstrated that DEX, in all tested concentrations, was not sufficient to notably induce the tenogenic differentiation of human DFs and DEX-treated organoids did not have clear advantages over untreated control organoids. Moreover, high concentrations of DEX exerted a negative impact on the organoid phenotype. Nevertheless, the expression profile of tendon-related genes of untreated and 10 nM DEX-treated DF organoids was largely comparable to organoids formed by tendon-derived cells, which is encouraging for further investigations on utilizing DFs for tendon tissue engineering.},
  language  = {en}
}